Bone Therapeutics Restates Priorities

Bone Therapeutics will not pursue the U.S. clinical development of PREOB® autologous cell therapy. In the U.S., priority will be given to the development of ALLOB®, with clinical programs to be developed during 2017. PREOB remains under clinical study in Europe.

Bone Therapeutics will retain its focus on the ALLOB allogeneic platform in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us